This biotech’s stock rockets on oral obesity drug partnership with Wegovy parent

marketwatch.com/story/this-biotechs-stock-rockets-on-oral-obesity-drug-partnership-with-wegovy-parent-56c8de52

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments.

This story appeared on marketwatch.com, 2025-05-14 13:00:00.
The Entire Business World on a Single Page. Free to Use →